CPhI Online

- Biopharma News

Almac expands global biologics testing services with mass spectrometry investment

26 Jan 2021

The company's £0.5 million investment in mass spectrometry support accelerates biologics development and approval

Building on the launch of its new biologics testing services last September, Almac Sciences, a member of the Almac Group, has announced additional expansion of its biologics testing laboratory with significant investment in mass spectrometry equipment.

Specifically, the company has installed a new high-resolution mass spectrometer at its global headquarters, located in Northern Ireland, and will support its biologics offering for the analysis of peptides, proteins, glycoproteins and antibody products.

This adds to the existing industry support at its new biologic testing laboratory based in Athlone, Ireland, announced just 3 months ago, which supports quality control release and characterisation of biologics.

The £500,000 investment in a Thermo Orbitrap LC-MS instrument substantially increases the company’s capabilities in solving biologic analytical challenges.

The instrument is capable of offering a complete analysis package to cGMP including amino acid sequencing, peptide mapping, disulfide bridge analysis using MS and MS/MS, glycosylation analysis, identification of post-translational modifications, for example, acetylation, phosphorylation in addition to biomarker discovery.

With this additional service, clients will benefit from an extended range of mass spectrometry services including the quantitation of genotoxic impurities, structure elucidation, isotopic purity determinations and high-resolution mass spectrometry of both large and small molecules.

Read More

Related Content